



Ishita Drugs & Industries Limited

"Our basic drugs in the service of humanity worldwide"

25th ANNUAL REPORT 2017-18

TWENTY- FIFTH ANNUAL REPORT AND ACCOUNTS

Board of Directors : Mr. Jagdish Agrawal - Managing Director

Mr. P. R. Rastogi - Director
Mr. Govind Gupta - Director
Dr. S. K. Agrawal - Director
Mrs. Abha Agrawal - Director
Mr. Niranjan Agrawal - Director

Bankers : Corporation Bank

ICICI Bank Ltd.

Punjab National Bank

Auditors : Mr. Pratik Kaushikkumar Kikani

Chartered Accountants,

Ahmedabad.

Secretarial Auditor : M/s. Meenu Maheshwari & Associates

Company Secretaries

Ahmedabad

Corporate Office : 401, 3rd EYE -II, Opp.Parimal Garden,

C.G.Road, Ahmedabad - 380 006.

Registered Office &

Factory

: Survey No. 179/1, Village : Vasna-Iyava,

Taluka: Sanand, District: Ahmedabad

Website : <u>www.ishitadrugs.com</u>

Investors' Complaints may

be addressed to

: Mr.Suresh Parmar Share Department

at Corporate office.

E-mail: <u>investors@ishitadrugs.com</u>

ANNUAL GENERAL MEETING

On Saturday, 29th September, 2018 at 3.00 P.M. at Registered Office of the Company

NOTICE TO THE SHAREHOLDERS

NOTICE is hereby given that the **TWENTY- FIFTH ANNUAL GENERAL MEETING** of the Members of **ISHITA DRUGS AND INDUSTRIES LIMITED** (CIN L24231GJ1992PLC017054) will be held on Saturday, 29th September, 2018 at 3.00 P.M. at the Registered Office of the Company situated at Survey No. 179/1, Vasna-Iyava, Tal. Sanand, Dist. Ahmedabad to transact the following business:

ORDINARY BUSINESS:

- To receive, consider and adopt the Statement of Profit & Loss for the year ended on 31st March, 2018, and the Balance Sheet as on that date, Directors' Report and the Auditors' Report thereon.
- To appoint a Director in place of Mrs. Abha Agrawal (DIN 01589479), who retires by rotation and, being eligible, offers herself for reappointment.
- To appoint the Auditors of the Company for the financial year 2018-19 pursuant to the provisions of section 139 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed there under, as amended from time to time and to fix their remuneration.

SPECIAL BUSINESS:

4. Re-appointment of Managing Director:

To consider and if thought fit, to pass, with or without modification the following resolution as a **Special Resolution**.

"RESOLVED THAT subject to the pursuant to the provisions of section 196, 197, 203 and other applicable provisions, if any, of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 framed there under, as amended from time to time, Shri Jagdish Agrawal, be and is hereby appointed as Managing Director of the Company for a period of 3 years w.e.f. 01.10.2018, not liable to retire by rotation, on the remuneration including salary and perquisites to be paid or granted to him as laid out in the draft agreement between the Company and Shri Jagdish Agrawal placed before the meeting and initialed by the Chairman of the Board for the purpose of identification, be and the same is hereby approved."

"RESOLVED FURTHER THAT the Board of Directors of the Company, be and is hereby authorized further to increase, enlarge, vary and including salary, dearness allowances, perquisites, commission and other allowance etc. up to the limits prescribed in this behalf under Schedule V of the companies Act, 2013 or any further statutory revision, modification, clarification or re-enactment thereof for the time being in force and / or the guidelines for managerial remuneration issued by the Central Government from time to time and from the date the statutory provisions and / or the guidelines coming into force without any further reference to the Company in General Meeting.

"RESOLVED FURTHER THAT the Board of Directors of the Company, be and is hereby authorized to do all such acts, deeds, things, matters as may be considered necessary, desirable or expedient to give effect to this Resolution."

For and on behalf of the Board

Sd/Place: Ahmedabad Jagdish Agrawal
Dated: 29th May, 2018 Managing Director

NOTES:

- a) A Member entitled to attend and vote is entitled to appoint one or more proxies to attend and vote instead of him and not later than 48 hours before the time fixed for holding the meeting.
- b) Members are requested to advise immediately any change in their address to the Company.
- c) Corporate members intending to send their authorized representative(s) to attend the Meeting are requested to send a certified copy of Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting
- d) In case of Joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote
- e) Member Register and Share Transfer books shall remain closed from 22.09.2018 to 29.09.2018 (both days inclusive).
- f) Members may avail of the facility of nomination in terms of section 72 of the Companies Act, 2013 by nominating any person to whom their shares in the Company shall vest on occurrence of events stated in Form SH-13. Form SH-13 is to be submitted in duplicates to Bigshare Services Private Limited. (Bigshare), RTA of the Company. In case of shares held in dematerialized form, the nomination has to be lodged with the respective Depository Participant.
- g) Relevant documents referred to in the accompanying notice or the statutory registers, as applicable to the Company, are open for inspection at the Registered Office of the Company on all working days (barring Saturday and Sunday) between 11:00 a.m. to 5:00 p.m. prior to the date of the AGM
- Members who have not registered their e-mail address so far are requested to register their e-mail address for receiving all communication including Annual Report, Notices, Circulars, etc, from the Company electronically
- i) In line with the 'Green Initiative in the Corporate Governance' launched by the Ministry of Corporate Affairs, Electronic copy of the Notice of the 25th Annual General Meeting of the Company inter alia indicating the process and manner of e-voting along with Attendance Slip and Proxy Form are being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) and have given their positive consent to receive the same through electronic means. Members other than above, physical copies of the Notice of the 25th Annual General Meeting ot the company inter alia indicating the process and manner of e-voting along with Attendance Slip and Proxy Form are being sent in the permitted mode.
- j) The Securities and Exchange Board of India (SEBI) has decided that securities of listed companies can be transferred only in dematerialised w.e.f. December 05, 2018 onwards. In view of the above and to avail various benefits of dematerialisation, members are advised to dematerialise shares held by them in physical form.
- k) Non Resident Indian members are requested to inform Bigshare / respective DPs, immediately of:
 - a. Change in their residential status on return to India for permanent settlement.
 - b. Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.
- Members may also note that the notice of the 25th Annual General Meeting and the Annual Report for the year 2017-18 will

ELECTRONIC VOTING PARTICULARS

EVEN (Electronic Voting Event Number)	User ID	Password

- also be available on the company's website www.ishitadrugs.com for their download.
- m) Members seeking any information or clarification from the accounts are requested to send written queries to the Company atleast 10 days before the date of the meeting to enable the management to keep the required information available at the meeting.
- n) A route map showing directions to reach the venue of the 25th Annual General Meeting is given along with this Annual Report as per the requirement of Secretarial Standards – 2 on General Meetings.

o) Voting through electronic means

- I. In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the AGM ("remote e-voting") will be provided by National Securities Depository Limited (NSDL).
- II. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting who have not cast their vote by remote e-voting shall be able to exercise their right at the meeting through ballot paper.
- III. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- IV. The e-voting facility will be available during the voting period as indicated herein below:

Commencement of e-voting	End of e-voting
26 th September, 2018	28 th September, 2018
at 10:00 am IST	at 5:00 pm IST

During this period members of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 22nd September, 2018, may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.

- V. The process and manner for remote e-voting are as under:
- Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
- ii. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholders' section.
- iii. A new screen will open. You will have to enter your User ID, your Password and a Verification Code as shown on the screen. Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
- iv. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.

b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************************************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

- v. Your password details are given below:
- a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
- (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
- (ii) If your email ID is not registered, your 'initial password' is communicated to you on page 3 of the Report.
- vi. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
- Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
- b) "Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
- vii. If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address
- viii. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
- ix. Now, you will have to click on "Login" button.
- After you click on the "Login" button, Home page of e-Voting will open.

${\bf Step\,2: Cast\,your\,vote\,electronically\,on\,NSDL\,e\text{-}Voting\,system.}$

- After successful login at Step 1, you will be able to see the Home page of e-Voting. Click on e-Voting. Then, click on Active Voting Cycles.
- After click on Active Voting Cycles, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle is in active status.
- iii. Select "EVEN" of company for which you wish to cast your vote.
- iv. Now you are ready for e-Voting as the Voting page opens.
- Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- vi. Upon confirmation, the message "Vote cast successfully" will be displayed.
- vii. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- viii. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

VI. General Guidelines for shareholders

1 Institutional shareholders (i.e. other than individuals, HUF, NRI

etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to maheshwarics@yahoo.com with a copy marked to evoting@nsdl.co.in.

- 2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990 or send a request at evoting@nsdl.co.in
- You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).
- 5. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cutoff date of 22nd September, 2018.
- 6. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. 22nd September, 2018, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or bssahd@bigshareonline.com.
 - However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password" option available on www.evoting.nsdl.com or contact NSDL at the following toll free no.: 1800-222-990.
- A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting or voting at the AGM through ballot paper.
- Meenu Maheshwari, Practicing Company Secretary of Meenu Maheshwari & Associates has been appointed as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote e-voting process in a fair and transparent manner.
- The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of "Ballot Paper" for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting facility.
- 10. The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than three days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- 11. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company (www.ishitadrugs.com) and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the BSE Limited. Mumbai.

By order of the Board of Directors For Ishita Drugs & Industries Ltd.

Sd/-

Place: Ahmedabad Dated: 29th May, 2018

Jagdish Agrawal Managing Director

Explanatory Statement pursuant to Section 102(1) of Companies Act, 2013

Item No. 4

Mr. Jagdish Agrawal is looking after the overall management of the Company. His term of appointment expires on 01.10.2018. Pursuant to the recommendation of the Nomination and Remuneration Committee, the Board of Directors, proposes to reappoint him for a period of 3 years from 1st October, 2018 on the terms and conditions mentioned herein below:

- Salary: In the range of ₹2,00,000 ₹3,00,000 per month, within which his basic salary, house rent allowance, special allowances, LTA, other allowances etc. would be determined, with annual increments, within the aforesaid range, as may be decided by the Board in accordance with the company's policy and provisions of Schedule V of the Companies Act, 2013.
- Perquisites: In addition to Salary Mr. Jagdish Agrawal will be entitled to the following perquisites / benefits.

CATEGORY-A

MEDICAL REIMBURSEMENT

Expenses incurred for the Director and his family, subject to a ceiling of one month's salary over a period of one year. It may include, inter-alia, payment of premium for health insurance for the Director and his family, within the limits as mentioned earlier.

LEAVE TRAVEL CONCESSION

For self and his family once in a year in accordance with the rules of the Company.

PERSONAL ACCIDENT INSURANCE

Premium not exceeding ₹35000/- per annum.

CATEGORY-B

- Company's contribution towards provident fund as per the rules of the Company
- Company's contribution towards superannuation fund as per the rules of the Company.
- Gratuity as per the rules of the Company not exceeding one half month's salary for each completed year of service as a Director.

CATEGORY-C

- Free telephone facility at residence.
- Provision of car with driver.
- Leave on full salary and perquisites for a period of one month for every eleven months service subject to a condition that leave accumulated but not availed of will not be allowed to be encashed.
- The Director shall also be entitled to reimbursement of entertainment expenses actually and properly incurred in the course of business of the Company.

The remuneration, inclusive of salary and perquisites, of Mr. Jagdish Agrawal would be governed by and subject to the ceilings prescribed under Schedule V to the Companies Act, 2013, or any other amendment, modification, verification or re-enactment thereof.

The explanatory statement together with the notice should be treated as an abstract of the terms of Agreement and Memorandum of concern or interest under section 190 of the Companies Act, 2013. Mr. Jagdish Agrawal is deemed to be concerned or interested in Resolution which pertains to his appointment and remuneration payable to him. Further Mrs. Abha Agrawal is deemed to be concerned in this resolution being relative of Mr. Jagdish Agrawal. None of the other Directors is concerned or interested in this Resolution.

Explanatory Statement pursuant to SECTION II OF PART II OF SCHEDULE V TO THE COMPANIES ACT, 2013 ITEM No. 4

I. GENERAL INFORMATION ABOUT THE COMPANY

(i) Nature of the Industry

The company is engaged in the business of manufacturing of various APIs (Active Pharma Ingredients) and drug intermediates. It has built up a reputation as a manufacturer of "high quality" products and is known for its ethical dealings in business. The company supplies its products to leading pharmaceutical companies of India. The products are also being exported to various countries across the world.

The management's view on the business operations and financial performance of the company, including export performance and earnings, is given under the Directors' Report forming part of the Annual Report of the company.

- (ii) Date or expected date of Commencement of Commercial production: The Company was incorporated on 5th February, 1992 as a Public Limited Company and the Certificate of Commencement of Business was obtained on 14th February 1992. The company had commenced commercial production by late 1997.
- (iii) In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: Not Applicable.
- (iv) Financial performance based on given indicators Its already described in Director Report as well as Auditor report forming part of the Annual Report of the Company.
- (v) Foreign Investment or collaborations, if any: The Company has not entered into any foreign collaboration. The Company has not made any foreign investments.

II. INFORMATION ABOUT THE APPOINTEE

Mr. Jagdish Agrawal, the Managing Director of the Company, has been associated with the company right from the conceptual stage till date. His current tenure is for a period of 3 years w.e.f 01.10.2018.

Mr. Jagdish Agrawal is a highly qualified person with a B. E. (Chemical Engineering) from U.D.C.T. Mumbai and a M.S. (Chem. Engg.) from University of Florida, USA. He has over 40 years of experience in the chemicals and pharmaceuticals industry and is widely acknowledged as an industry expert. He is a member of various Govt. Committees and Industry Association committees, in an advisory and executive role. He is also a first generation entrepreneur and often lectures at prestigious institutes of Ahmedabad on that subject. He was honoured with the UDYOG PATRA Award in 1982 at the hands of the Vice – President of India.

He has been at the helm of your Company for many years and is responsible for the overall strategic growth of the company as well as the day-to-day functioning of the company. Under his leadership, the company has been able to turn around and wipe out all carried forward losses. Being an industry expert, he provides invaluable technical guidance to the production department and is fully involved at a micro level with all issues pertaining to the factory and production. He is also liasoning with various regulatory bodies and govt. departments.

Under his leadership, your Company was declared as the "BEST SME FOR CORPORATE GOVERNANCE (SMALL)" at the Business Today – Yes Bank SME Awards 2011 in New Delhi. The award is a reflection of the high ethical standards and transparency adopted by the company, under the leadership of Mr. Jagdish Agrawal, in its business dealings and serving of shareholders' interests.

The present remuneration of the Managing Director includes a salary of ₹ 200000/- per month and other perquisites. The remuneration has been **kept at the same level** for the last **SIX**

vears.

The present salary is below the industry standard of salary for similarly qualified and experienced professionals at such high positions. In the last few years, the remuneration levels in the pharmaceutical industry have gone up significantly, at all levels and across all sizes of industry. It is becoming increasingly difficult to retain technically qualified people at lower salary levels.

It is now proposed to re-appoint Mr. Jagdish Agrawal at a salary range of ₹ 200000/- to ₹ 300000/- per month and other perquisites, as per details given in the Notice to the AGM along with the Explanatory statement(s) forming part of the Notice, subject to approval of the shareholders

Mr. Jagdish Agrawal is related to Mr. Sumit Agrawal, CFO of your company and Mrs. Abha Agrawal, Director of your Company.

III. OTHER INFORMATION

The company is presently in a phase of financial consolidation. The difficult times faced by the company during its initial years of operations had resulted in carried forward losses, which the company has been able to wipe off in the last few years. On account of its prior experiences, the company is presently working in certain low volume high margin niche products and also limiting its sales to few select prestigious customers. Consequently, the profits of the company are presently seen to be inadequate.

However, the company is now focusing on adjusting its growth strategy with the rapidly changing economic scenario. The present consolidation phase will provide a good launching pad to the company. The company is also working with some international merchant exporters to increase its exports as also trying to identify some high volume, low margin products to improve capacity utilization of its facilities. All these steps should improve the working of the company in the next few years.

IV. DISCLOSURES

The information and disclosures of the remuneration package of the managerial personnel have been mentioned in the Annual report in the Corporate Governance Report Section under the heading "Remuneration paid / payable to Managing / Executive Director (Whole – time Director) for the year ended 31st March, 2018

The proposed remuneration of the Managing Director is within the ceiling limits prescribed under Schedule V of the Companies Act, 2013. The proposed enhancement in salary has been approved by a resolution passed by the Remuneration Committee.

The explanatory statement together with the notice should be treated as an abstract of the terms of Agreement and Memorandum of concern or interest under section 190 of the Companies Act, 2013. Mr. Jagdish Agrawal is deemed to be concerned or interested in this resolution, as resolutions at Item No.4 pertains to his re-appointment and fixing of his remuneration. Mrs. Abha Agrawal is deemed to be concerned in this resolution being relative of Mr. Jagdish Agrawal. None of the other Directors is concerned or interested in this Resolution.

By order of the Board of Directors For Ishita Drugs & Industries Ltd.

Place: Ahmedabad Dated: 29th May, 2018 Sd/-**Jagdish Agrawal** Managing Director

DIRECTORS' REPORT

Dear Shareholders,

We have pleasure in presenting the **Twenty- Fifth Annual Report** together with the Audited Accounts of your Company for the year ended on 31st March-2018.

WORKING RESULTS

₹ in Lacs

	For the year ended 31.03.2018	For the year ended 31.03.2017
Turnover & other incomes	701.91	652.06
Operating gross profit	57.19	44.16
Financial Charges	(11.26)	(4.46)
Depreciation	(13.61)	(14.00)
Profit before tax & after	32.32	25.70
exceptional items		
Provision for Income Tax	(8.00)	(8.50)
Provision for Deferred Tax	0.46	1.04
Previous period adjustment	0.00	0.00
Net profit / loss (-)	24.78	18.25

DIVIDEND

With a view to consolidate the financial position of the Company, the Board has not recommended any dividend for the year under review.

BUSINESS OPERATIONS & FINANCIAL PERFORMANCE

The year under review saw the implementation of the Goods and Services Tax (GST) in India, which was one of the most significant tax reforms undertaken in the last couple of decades. The GST is a single indirect tax and subsumed many other indirect taxes and levies. As expected there were initial teething problems with the implementation and the business environment remained subdued for the first half of the year under review due to the uncertainity, ambiguity and confusion regarding the new taxation laws. However, the situation improved thereafter and the total revenues of the Company increased to ₹ 701.92 lakh in the year under review, compared to ₹ 652.06 lakh in the previous year, partly on account of increase in exports of the Company.

There were further challenges for the Company during the year under review as there was erratic supply, and volatility in prices, of some major raw materials of the company, due to shut down of various chemical factories in China. Fortunately, your Company was able to pass through part of the increase in raw material prices to its customers. Further, due to availability of GST credit on various interstate purchases and other expenses which were not previously available, the operating profits of the company improved from ₹ 44.16 lakh in the previous year to ₹ 57.19 lakh in the year under review.

The net profit of the company also increased from ₹ 18.25 lakh in the previous year to ₹ 24.78 lakh in the year under review, largely on account of better operating profits.

FUTURE OUTLOOK

The GST mechanism has now stabilized and we hope that its benefits would help improve the business environment in the country and lead to long term growth for industry.

The Company is focusing on increasing its exports to various countries and plans to undertake minor upgradation of its facilities to obtain the certification required for exports to more countries.

The Govt. of India (GoI) has recognised that India's Active Pharma Ingredients (API) industry has been facing problems in the past few years, mainly due to low-cost imports from China. The GoI has declared a policy to promote API industry in the current year. Your Company hopes that all above factors would help improve its performance in the near future.

DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

The Company has adequate and effective internal controls to provide reasonable assurance on achievement of its operational, compliance and reporting objectives. The Company has reviewed and discussed with the Management the Company's major financial risk exposures and taken steps to monitor and control such exposure.

DETAILS OF SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES

Your Company does not have any Subsidiary or Joint Venture or Associate Company.

FIXED DEPOSIT

The Company has not accepted any fixed deposit from the public during the year. (PY₹NIL).

STATUTORY AUDITORS

The Company, in its last annual general meeting, had appointed Pratik Kaushikkumar Kikani, Chartered Accountants, as auditors for the year 2017-18. The remarks made in the Auditors' report are self-explanatory.

For the financial year 2018-19, it is proposed to appoint Pratik K. Kikani & Associates, Chartered Accountants, Ahmedabad, as the statutory auditors of the company, as per the provisions of Section 139 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, including any amendments if any thereof.

SHARE CAPITAL

The paid up capital of the Company is ₹ 2,99,03,000/-. Your Company has not issued any kind of Shares during the financial Year ended on 31st March, 2018.

EXTRACT OF THE ANNUAL RETURN

The extract of the annual return in Form No.MGT – 9 shall form part of the Board's report and is set out as **Annexure A** to this Report.

PARTICULARS OF EMPLOYEE

There are no employees employed by the Company throughout the financial year or for a part of the financial year who were drawing remuneration above the limits provided in section 197 (12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and therefore there are no details required to be given in the report.

DIRECTORS

(a) Mrs. Abha Agrawal (DIN 01589479) retires by rotation, and being eligible, has offered herself for reappointment. The Board recommends her re-appointment.

(b) Declaration by an Independent Director(s) and re- appointment, if any: A declaration by an Independent Directors that they meet the criteria of independence as provided in sub-section (7) of Section 149 of the Companies Act, 2013 has been received and taken on note.

DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM FOR DIRECTORS AND EMPLOYEES

The Company promotes ethical behavior in all its business activities and has put in implementation of a mechanism wherein the Employees are free to report illegal or unethical behavior, actual or suspected fraud or violation of the Company's Codes of Conduct or Corporate Governance Policies or any improper activity to the Chairman of the Audit Committee of the Company or Chairman of the

25th ANNUAL REPORT 2017-18

Company or the Compliance Officer. The Whistle Blower Policy has been appropriately communicated within the Company. Under the Whistle Blower Policy, the confidentiality of those reporting violation(s) is protected and they are not subject to any discriminatory practices. No personnel have been denied access to the Audit Committee.

PARTICULARS OF LOANS GUARANTEES OR INVESTMENTS UNDER SECTION 186

The company has not given any loans or guarantees covered under the provisions of section 186 of the Companies Act, 2013. The details of the investments made by company are given in the notes to the financial statements.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

The particulars of every contract or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto shall be disclosed in Form No. AOC-2. However your company has not entered in any transaction attracting provision of Section 188 of Companies Act, 2013. Hence AOC-2 is not required to be attached.

DISCLOSURES RELATING TO MANAGERIAL REMUNERATION

The information required under Section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of Directors / employees of your Company is set out in **Annexure B** to this report. Your Company does not have any employee, who was in receipt of remuneration in excess of limits specified in the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

SECRETARIAL AUDIT

A Secretarial Audit Report given by Ms. Meenu Maheshwari, a company secretary in practice (C.P. No. 8953) is set out as **Annexure C** to this Report. The Report contains observation about non-payment of listing fees within the prescribed time. However, your Company has protested and disputed the unprecedented abnormal increase in listing fees for the year under review and written to the concerned stock exchange. The shares of the Company continue to be actively listed and traded on the said stock exchange.

RISK MANAGEMENT POLICY

A statement indicating development and implementation of a risk management policy for the Company including identification therein of elements of risk, if any, which in the opinion of the Board may threaten the existence of the company.

The Board of Directors has duly developed and implemented a risk management policy for the company.

CODE OF CONDUCT

The Board has laid down a Code of Conduct for Board Members and for Senior Management and Employees of the Company ("Code"). All the Board Members and Senior Management Personnel have affirmed compliance with these Codes. A declaration signed by the Managing Director to this effect is enclosed at the end of this Report.

The Board has also laid down a Code of Conduct for Independent Directors pursuant to section 149(8) and Schedule IV to the Companies Act, 2013 via terms and conditions for appointment of Independent Directors, which is a guide to professional conduct for Independent Directors and is uploaded on the website of the Company.

DISCLOSURE UNDER THE SEXUAL HARRASMENT OF WOMAN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSALACT, 2013

The Company has been employing about two women employees.

The Company has in place an Anti harassment policy in line with the requirements of the Sexual Harassment of Woman at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee is set up to redress complaints received regularly, is monitored and directly report to the Chairman & Managing Director. There was no complaint received from employee during the financial year 2017-18 and hence no complaint is outstanding as on 31.03.2018 for redressal.

DIRECTOR RESPONSIBILITY STATEMENT:

Your Directors confirm:

- that in the preparation of annual accounts, the applicable accounting standards have been followed;
- ii. that the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March, 2018 and of the profit of the Company for the year;
- iii. that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of Companies Act, 2013, for safeguarding the assets of the Company for preventing and detecting fraud and other irregularities;
- iv. that the Directors have prepared the annual accounts on a going concern basis

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant/material orders passed by the Regulators or Courts or Tribunals impacting the going Concern status of your Company and its operations in future.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO

The statement containing the necessary information required under Section 134 of the Companies Act, 2013, read with Rule 8(3) of the Companies (Accounts) Rules, 2014 [Chapter IX] is annexed herewith as **Annexure D**.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis, for the year under review, as stipulated in SEBI (LODR), 2015, is presented in a separate section forming part of this Annual Report.

CORPORATE GOVERNANCE

Provisions of Regulation 27 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015, relating to corporate governance are not applicable to the Company. However, with a view to increase investors' trust and transparency in its operations, the Board has decided to voluntarily adopt and follow some of the provisions of the aforesaid regulations. A separate Report on Corporate Governance forms part of this Annual Report.

ACKNOWLEDGMENT

Place: Ahmedabad

Dated: 29th May, 2018

We wish to place on record our deep appreciation of the co-operation and assistance received by the Company from the staff and employees. We further wish to thank our bankers for their continued support to the Company.

For and on behalf of the Board

Sd/-**Jagdish Agrawal** Managing Director

ANNEXURE A TO THE BOARD'S REPORT EXTRACT OF ANNUAL RETURNS AS ON $31^{\rm ST}$ MARCH 2018

Form No. MGT-9

[Pursuant to Section 92(3) of the Companies Act,2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

1.	CIN	L24231GJ1992PLC017054
2.	Registration Date	5 th February 1992
3.	Name of the Company	ISHITA DRUGS & INDUSTRIES LTD
4.	Category of the Company	PUBLIC COMPANY
	Sub-Category of the Company	COMPANY HAVING SHARE CAPITAL
5.	Address of the Registered office and contact	SURVEY NO.179/1, VILLAGE VASNA-IYAVA, TAL SANAND,
	details	DIST AHMEDABAD-382170. Contact : ishitadrugs@vsnl.net
6.	Whether listed company	Yes
7.	Name, Address and Contact details of Registrar	Bigshare Services Private Limited, E-3, Ansa Industrial Estate,
	and Transfer Agent, if any	Saki Vihar Road, Sakinaka, Mumbai – 400072, Maharashtra
		Mumbai-400072
		Contact : bssahd@bigshareonline.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

Sr.No.	Name and Description of main products/ services	• •		
1	Bulk Drugs, Fine Chemicals and Intermediates	Chapter 28 & 29 products	100%	

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

The Company does not have any holding, subsidiary or associate company.

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during The year
	Demat	Physical	Total	%of	Demat	Physical	Total	% of	
				Total				Total	
				Shares				Shares	
A. Promoter									
1) Indian									
a) Individual/ HUF	870181	109400	979581	32.76	870181	109400	979581	32.76	0.00
b) Central Govt			-		-	-	-	-	
c) State Govt(s)									
d) Bodies Corp	427300	0	427300	14.29	427300	0	427300	14.29	0.00
e) Banks / FI									
f) Any Other									
Sub-total(A)(1):-	1297481	109400	1406881	47.05	1297481	109400	1406881	47.05	0.00
2) Foreign									
g) NRIs-Individuals									
h) Other-Individuals									
i) Bodies Corp.									
j) Banks / Fl									
k) Any Other			-					-	
Sub-total(A)(2):-									

25th ANNUAL REPORT 2017-18

B. Public Shareholding									
1. Institutions									
a) Mutual Funds									
b) Banks / FI									
c) Central Govt									
d) State Govt(s)									
e) V. C. Funds									
f) Ins. Companies									
g) Flls								[
h) Foreign Venture									
Capital Funds									
i) Others (specify)									
Sub-total(B)(1)									
2. Non Institutions									
a) Bodies Corp.									
(i) Indian	101656	3100	104756	3.50	95014	3100	98114	3.28	(0.22)
(ii) Overseas									
b) Individuals									
(i) Individual	765827	479545	1245372	41.65	688238	473645	1161883	38.86	(2.79)
shareholders									
holding nominal									
share capital upto									
₹2 lakh									
(ii) Individual	187204	0	187204	6.26	228931	0	228931	7.66	1.40
shareholders									
holding nominal									
share capital in									
excess of									
Rs 2 lakh									
c) Others									
(i) Clearing Members	3405	0	3405	0.11	600	0	600	0.02	(0.09)
(ii) NRI	31082	0	31082	1.04	82291	0	82291	2.75	1.71
(iii) NBFC Registered	11500	0	11500	0.38	11500	0	11500	0.38	0.00
with RBI									
(iv) Trusts	100	0	100	0.00	100	0	100	0.00	0.00
Sub-total(B)(2)	1100774	482645	1583419	52.95	1106674	476745	1583419	52.95	0.00
Total Public	1100774	482645	1583419	52.95	1106674	476745	1583419	52.95	0.00
Shareholding									
(B)=(B)(1)+ (B)(2)									
C. Shares held by									
Custodian for GDRs									
& ADRs	ļ								
Grand Total									
(A+B+C)	2398255	592045	2990300	100.00	2404155	586145	2990300	100	0.00

^{*} Previous year figures have been regrouped and reclassified to be in conformity with the current year figures.

ii. Shareholding of Promoters

Sr. No	Shareholder's Name	Shareholding at the beginning of the year			Sharehol the year			
		No. of Shares	% of total Shares	%of Shares Pledged to total shares	No. of Shares	% of total Shares	% of Shares Pledged to total shares	% change in share holding during the year
1.	PRATIBHA AGRAWAL	8200	0.27	NIL	8200	0.27	NIL	0.00
2.	VIRENDRA AGRAWAL	33250	1.11	NIL	33250	1.11	NIL	0.00
3.	VIRENDRA AGRAWAL	1800	0.06	NIL	1800	0.06	NIL	0.00
4.	MAHESH AGRAWAL	750	0.03	NIL	750	0.03	NIL	0.00
5.	ANJALI AGRAWAL	51500	1.72	NIL	51500	1.72	NIL	0.00
6.	AGRAWAL JAGDISHPRASAD G	85000	2.84	NIL	85000	2.84	NIL	0.00
7.	ABHA AGRAWAL	138259	4.62	NIL	138259	4.62	NIL	0.00
8.	JAGDISH AGRAWAL	232913	7.79	NIL	232913	7.79	NIL	0.00
9.	ISHITA AGRAWAL	25140	0.84	NIL	25140	0.84	NIL	0.00
10.	SUMIT AGRAWAL	239719	8.02	NIL	239719	8.02	NIL	0.00
11.	DIVYA PIPRIYA	89150	2.98	NIL	89150	2.98	NIL	0.00
12.	UMANG FINANCIAL SERVICES LTD.	297300	9.94	NIL	297300	9.94	NIL	0.00
13.	ISHITA OVERSEAS PVT.LTD.	130000	4.35	NIL	130000	4.35	NIL	0.00
14.	PRATIBHA AGRAWAL	1800	0.06	NIL	1800	0.06	NIL	0.00
15.	SUMAN AGRAWAL	12000	0.40	NIL	12000	0.40	NIL	0.00
16.	SUMIT AGRAWAL	60000	2.01	NIL	60000	2.01	NIL	0.00
17.	VIRENDRA AGRAWAL	100	0.00	NIL	100	0.00	NIL	0.00
	Total	1406881	47.05		1406881	47.05		

iii. Change in Promoters' Share holding

No change in shareholding of any promoter

V. <u>INDEBTEDNESS</u>

Indebtedness of the Company including interest outstanding /accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
	₹	₹	₹	₹
Indebtedness at the beginning of the financial year				
i) Principal Amount	72229			72229
ii) Interest due but not paid				
iii) Interest accrued but not				
Total(i+ii+iii)	72229			72229
Change in Indebtedness during the financial year				
- Addition	1275000	48000		1323000
- Reduction	(105540)	(22738)		(128278)
Net Change	1169460	25262		1194722
Indebtedness at the end of the financial year				
i) Principal Amount	1241689	25262		1266951
ii) Interest due but not paid				
iii) Interest accrued but not due				
Total (i+ii+iii)	1241689	25262		1266951

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director

SI. No.	Particulars of Remuneration	Mr. Jagdish Agrawal	Total Amount (₹)
1.	Gross salary	2400000	2400000
2.	Stock Option	0	0
3.	Sweat Equity	0	0
4.	Commission	0	0
5.	Others, please specify	0	0
6.	Total (A)	2400000	2400000
	Ceiling as per the Act*		6000000

^{*} Remuneration to Managing Director is within the limits prescribed under Schedule V to the Companies Act, 2013

B. Remuneration to other Directors:

No remuneration including seating fees is being paid to any other Director.

C. Remuneration to Key Managerial Personnel Other Than MD

SI. no.	Particulars of Remuneration	Key Managerial Personnel				
		CFO (Sumit Agrawal)	Total ₹			
1.	Gross salary	2100000	2100000			
2.	Stock Option	0	0			
3.	Sweat Equity	0	0			
4.	Commission	0	0			
5.	Others, please specify	0	0			
6.	Total	2100000	2100000			

VII. PENALTIES/ PUNISHMENT / COMPOUNDING OF OFFENCES:

No penalties/punishment/compounding of offences were levied under the Companies Act, 2013.

ANNEXURE B TO THE BOARD'S REPORT

Information required under section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rule, 2014

A. Ratio of Remuneration of each Director to the median remuneration of all the employees of your Company for the financial year 2017-18 is as follows:

Name of	Total	Ratio of remuneration
Director	Remuneration	of Director to the
	(₹)	median remuneration
Mr. Jagdish Agrawal	24.00.000/-	9.09

Notes: No remuneration is being paid to any other director. The median remuneration for all employees of the company has been calculated only for employees working with the company as on March 31, 2018.

B. Details of percentage increase in the remuneration of Director and CFO in the financial year 2017-18:

Name	Designation	Remuner	Increase	
		2017-18	2016-17	(%)
Jagdish Agrawal	M. D.	2400000	2400000	0.00
Sumit Agrawal	CFO	2100000	2100000	0.00

C. Percentage increase in the median remuneration of all employees in the FY 2017-18

It is not practical to ascertain the above as the type and number of employees at different levels has changed between FY 2016-17 & FY 2017-18.

D. Number of permanent employees on the rolls of the Company as on 31.03.18:15 (Fifteen)

E. Explanation on the relationship between average increase in remuneration and Company performance:

There was an increase of 1.36% in remuneration of all employees in the financial year 2017-18 as compared to the financial year 2016-17. The increase was possible due to better operating margins during the year and is largely in line with the increase in operating profits of the company. (Remuneration of only those employees was considered who were with the company in 2017-18 and 2016-17).

	Growth (%)
Total Revenues	7.65
Operating Profit	29.51
Profit After Tax	35.78

Your company offers competitive compensation to its employees. Also, the company has to offer salaries as per the prevailing industry rates, irrespective of the performance, to retain the employees. This ensures a healthy work environment and job satisfaction for the employees. Hence, there would be a positive co-relation in the increase in remuneration of the employees and the performance of the Company. However, a perfect co-relation will not be visible given the dependency of performance of the Company on other external factors.

F. Comparison of the remuneration of the Key Managerial Personnel against the performance of Your Company:

There was no increase in the remuneration of the Key Managerial Personnel while the operating profits of the company increased by 29.51% in the year 2017-18 compared to 2016-17.

G. Details of Share price and market capitalization

	As on 31 st	As on 31st	Increase /
	March 2018	March 2017	(Decrease) (%)
Closing Market Price on BSE	22.45	20.00	12.25
Price Earnings Ratio	27.09	32.77	(17.35)
Market Capitalization (₹. lakh)	671.32	598.06	12.25

Details of month wise highs and lows of the price of the shares of the company on the BSE and the volumes traded are given in the Report on Corporate Governance, forming a part of this Annual Report.

H. Comparison of average increase in salary of employees other than the key managerial personnel and the percentage increase in the key managerial remunerations:

There was an increase of 3.75% in the remuneration of all employees, excluding Key Managerial Personnel, during the year under review. There was no increase in the remuneration of Key Managerial Personnel in the financial year 2017-18 as compared to the financial year 2016-17 (Remuneration of only those employees was considered who were with the company in 2016-17 and 2017-18).

I. Key Parameters of the variable Component of remuneration paid to the director

The remuneration payable to the Director for the year 2017-18 does not include any variable component.

J. There are no employees of the Company who receive remuneration in excess of the highest paid Director of the Company.

K. Affirmation

Pursuant to Rule 5(1) (xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, Key Managerial Personnel and senior management is as per the Remuneration Policy of your Company.

L. Statement containing the particulars of employees in accordance with Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rule, 2014

The company has no such employees.

ANNEXURE C TO THE BOARD'S REPORT SECRETARIAL AUDIT REPORT Form No.MR-3

Form No.WH-3

For the financial year ended 31/03/2018 [Pursuant to section 204 (1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

The Members

ISHITA DRUGS AND INDUSTRIES LIMITED

SURVEY NO 179/1, VASNA-IYAVA TALUKA SANAND

AHMEDABAD - 382 170.

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. ISHITA DRUGS AND INDUSTRIES LIMITED (hereinafter called the 'Company'). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, I hereby report that in my opinion, the Company

25th ANNUAL REPORT 2017-18

has, during the audit period covering the financial year ended on 31st March, 2018, generally complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2018, according to the provisions of:

- The Companies Act, 2013("the Act") and the rules made thereunder as applicable;
- The Securities Contracts (Regulation) Act, 1956 ('SCRA') and
- the rules made thereunder; The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- Foreign Exchange Management Act, 1999 (FEMA) and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not applicable to the Company during the Audit Report)
- The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
 - The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)Regulations, 2009; (Not applicable to the Company during the Audit
 - The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; (Not applicable to the Company during the Audit Report)
 - The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not applicable to the Company during the Audit Report)
 - The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; (Not applicable to the Company during the Audit Report)
 - The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; (Not applicable to the Company during the Audit Report)
 - The Securities and Exchange Board of India (Buy back of Securities) Regulations, 1998; (Not applicable to the Company during the Audit Report)
- I have relied on the representation made by the Company and its officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws and Regulations to the Company. I have relied on the report of Statutory Auditors of the Company for compliance system relating to direct tax, indirect tax and other tax laws.

The list of other Acts, Laws and Regulations as applicable to the Company is as given below:-

- Drugs & Cosmetics Act, 1940,
- Narcotic Drugs and psychotropic Substances Act, 1985,
- Indian Boilers Act . 1923.
- Factories Act, 1948
- The Payment of Wages Act, 1936
- The Minimum Wages Act, 1948
- Employees' State Insurance Act. 1948
- The Employees' Provident Funds and Miscellaneous Provisions Act, 1952
- The Payment of Bonus Act, 1965
- The Payment of Gratuity Act, 1972
- Negotiable Instrument Act, 1881
- Sale of Goods Act, 1930
- Foreign Contribution Regulation Act, 2010 •
- Micro, Small and Medium Enterprises Development Act, 2006
- Income Tax Act, 1961
- Central Excise Act, 1944
- Customs Act. 1962

- Central Sales Tax Act, 1956
- VAT Act (State Acts)
- GST Act

Environmental Laws

- Water (Prevention and Control of Pollution) Act, 1974
- Water (Prevention and Control of Pollution) Cess Act, 1977
- Air (Prevention and Control of Pollution) Act, 1981
- Environment (Protection) Act, 1986
- Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 20081881

I have also examined compliance with the applicable clauses of the following:

- Secretarial Standards issued by the Institute of Company Secretaries of India (applicable for the period ending 31st March,
- Listing Agreements entered into by the Company with BSE (Stock Code: 524400) (BOMABAY STOCK EXCHANGE) Limited and ASE (Stock Code: 26940)(Ahmedabad Stock Exchange) and/or Securities Exchange Board Of India (Listing Obligations And Disclosure Requirement) Regulations, 2015

During the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations:

Company has not paid listing fees for the year 2017-18 to Stock Exchanges within prescribed time during the year under review.

I further report that -

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were no instances of;

- (i) Public/Rights/Preferential issue of shares/Debentures/Sweat
- Redemption/Buy-back of securities.
- Major decision taken by the members in pursuance to Section (iii) 180 of the Companies Act, 2013,
- (iv) Merger/Amalgamation/Reconstruction, etc.
- Foreign Technical Collaboration.

For Meenu Maheshwari & Associates

Sd/-Proprietor (Meenu Maheshwari) Company Secretaries Firm Regn No.: S2015GJ305400 FCS No. 7087 C.P. No. 8953

Date: 29.05.2018 Place: Ahmedabad

ANNEXURE A OF SECRETARIAL AUDIT REPORT

To, The Members, ISHITA DRUGS AND INDUSTRIES LIMITED SURVEY NO 179/1, VASNA-IYAVA TALUKA SANAND AHMEDABAD – 382 170.

My Report of even date is to be read along with this letter.

1) Management Responsibility:

(1) It is the responsibility of the management of the company to Maintain secretarial record, devise proper system to ensure compliance with the provisions of all applicable laws and regulation and to ensure that the system are adequate and operate effectively.

2) Auditors Responsibility:

- (2) I responsible am to express an opinion on this secretarial record, standards and procedure followed by the company with respect to secretarial compliances.
- (3) I believe that audit evidence and information obtained from the company's management is adequate and appropriate for us to provide a basis for our opinion.
- (4) Wherever required, I have obtained the management representation about the compliance of laws, rules and regulation and happening of events etc.
- (5) I have not verified the correctness and appropriateness of financial records and books of accounts of the Company, and The verification was done based on the records and documents provided, on test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices followed by me provide a reasonable basis for my opinion.
- (6) The compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on test basis.

3) Disclaimer:

The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the company.

For Meenu Maheshwari & Associates

Sd/Proprietor
(Meenu Maheshwari)
Company Secretaries
Firm Regn No.: S2015GJ305400
FCS No. 7087 C.P. No. 8953

Date: 29.05.2018 Place: Ahmedabad

ANNEXURE D TO THE BOARD'S REPORT

CONSERVATION OF ENERGY

The Company has been persistently striving to achieve improved efficiency in energy consumption by consistently running the plant at very high steam efficiency, close monitoring of energy consuming equipments, optimizing the use of steam centers minimizing losses and better housekeeping. The Company continues to make strenuous efforts to conserve and optimize the consumption of energy through improved operational methods.

FORM - A

Form for disclosure of particulars with respect to the conservation of energy.

POWER AND FUEL CONSUMPTION

	2017-18	2016-17
1) Electricity (a) Purchased units KWH (GEB) Total amount ₹ Average Rate per Unit ₹	116708 970874 8.32	122022 1004402 8.23
(b) Own Generation through D.G. Amount of Diesel Units of Diesel consumed (Ltrs)		
2) Other Fuels ₹	1017683	1031220

CONSUMPTION PER UNIT OF PRODUCTION

It is impractical to apportion the consumption and cost of utilities to each product in view of multiplicity of products.

RESEARCH AND DEVELOPMENT

The Company through its R&D efforts has made significant progress in various activities like Process Development, Analytical Methods, Development and Chemical Synthesis.

FORM-B

Form of disclosure of particulars with respect to the technology absorption.

- (A) Research and Development (R&D)
- 1. Specific areas in which R&D is carried out by the Company.
 - Process development for newer bulk drugs and process improvement for existing product
- Development of new analytical methods for quality control and quality assurance during production.
- 2. Benefits derived as a result
 - Successful Commercialization of the process developed by R&D department significant savings due to in house process development.
 - Better margins due to improvement in yields.
 - Improved quality of products due to adaptation of better methods of analysis by quality assurance.
- 3. Future plan of action

Research and Development efforts will be continued in process development. The Company is considering technical tie-ups with Indian and Foreign research institutes for new molecules in the chemical and biotechnology spheres.

4. Expenditure on R & D:

	2017-18	2016-17
(a) Capital		
(b) Recurring	₹ 146792	₹ 189407
Total (a+b)	₹ 146792	₹ 189407
(c) Total R&D expenditure as a	0.21%	0.25%
percentage of total turnover		

(B) Technology Absorption, Adaptation and Innovation

- 1. Efforts, in brief, made towards technology absorption, adaptation and innovation:
 - Our R&D laboratory has carried out detailed experiments for the Process development of drug intermediates.
- 2. Benefits derived as a result of the above efforts, e.g., development, import substitution, etc.:-
 - Commercial Production of the specialty chemical product (Drug Intermediate) may be taken up in near future.
- 3. In case of imported technology (imported during the last five years reckoned from the beginning of the financial year) Nil

(C) Foreign exchange earnings and outgo

- a) Foreign Exchange Earning ₹ 6184057 (PY ₹ 3774691)
- b) Foreign Exchange Outgo ₹ 20635050 (PY ₹ 23514621)

For and on behalf of the Board

Sd/Place: Ahmedabad Jagdish Agrawal
Dated: 29th May, 2018 Managing Director

REPORT ON CORPORATE GOVERNANCE & GENERAL SHAREHOLDER INFORMATION

A. REPORT ON CORPORATE GOVERNANCE

I. Company's philosophy on Corporate Governance:

Your company has always adapted the highest ethical standards in business and good Corporate Governance practices so that positive aspects of a "family-run" business are combined with the assurance that investors 'interests would be recognized and addressed. The salient features of the company's philosophy on corporate governance are:

- 1. Compliance with all Statutory laws as also other rules / requirements regarding directors / related person remuneration, disclosures, etc.
- 2. Clear separation of company owned resources and personal accounts
- 3. Reliance on structures and processes that are recognized as good and moral corporate practices rather on "family" persons, making it a truly professionally managed Company.
- 4. Full transparency in functioning and accountability of management to the Board
- Internal controls and Risk management under supervision of Independent Directors
 With transparent and honest administrative practices, the management of your company believes it can further increase investors trust and work responsibly to maximize all shareholders value.

II. Board of Directors:

Composition:

As on date, the Board of Directors of your Company comprises six (6) Directors of which four (4) are Non-Executive/Independent Directors, one (1) is a Non-Executive Promoter Director and one is Managing Director of the Company. The composition of the Board is in conformity with Regulation 27 and suitable applicable provisions of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (hereinafter referred to as "SEBI (LODR) Regulations, 2015"). The details of the Directors being appointed / re-appointed on retirement by rotation at the ensuing Annual General Meeting, as required pursuant to Regulation 27 and suitable applicable provisions of SEBI (LODR) guidelines, are mentioned in the Notice to the Annual General Meeting, forming part of the Report.

Number of Board Meetings:

During the financial year ended on March 31, 2018, four (4) meetings of the Board of Directors were held and the maximum time gap between two (2) meetings did not exceed four (4) months.

Date(s) on which meeting(s) were held:

Board Meeting was held on 30/05/2017, 14/08/2017, 13/11/2017 and 13/02/2018.

The Board meets at least once in a quarter to review the quarterly financial results and operations of the Company. In addition to the above, the Board also meets as and when necessary to address specific issues relating to the business.

Committees of the Board:

Currently, there are Three (3) Committees of the Board, namely: Audit Committee, Nomination & Remuneration Committee and Stakeholder Relationship committee. The Board decides the terms of reference for these Committees. The minutes / report of the meetings of the Committees are placed before the Board for information and action thereon, if any. The details as to the composition, terms of reference, number of meetings etc., of these Committees are provided hereunder:

AUDIT COMMITTEE:

The Committee comprises two independent directors and one non-independent director and is chaired by an Independent Director.

The constitution of Audit Committee meets with the requirements of Corporate Governance guidelines as well as the provisions of Section 177 of the Companies Act, 2013 and Regulation 27 and suitable applicable provisions of SEBI (LODR) guidelines. Terms of reference of appointment of Audit Committee are as under,

The Audit Committee shall have the following powers:

- It shall have authority to investigate into any matter in relation to the items specified in Section 177 of the Companies Act, 2013 or referred to it by the Board and for this purpose, shall have full access to information contained in the records of the Company and external professional advice, if necessary.
- > To investigate any activity within its terms of reference.
- > To seek information from any employee.
- > To obtain outside legal or other professional advice.
- > To secure attendance of outsiders with relevant expertise, if it considers necessary.
- Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible.

25th ANNUAL REPORT 2017-18

- Recommending the appointment and removal of external auditor, fixation of audit fees and also approval for payment for any other services.
- > Reviewing with management the annual financial statements before submission to the Board, focusing primarily on;
 - · Any changes in accounting policies and practices.
 - Major accounting entries based on exercise of judgment by management.
 - Qualification in draft audit report.
 - · Significant adjustments arising out of audit.
 - The going concern assumption.
 - · Compliance with accounting standards.
 - Compliance with stock exchange and legal requirements concerning financial statements.
 - Any related party transactions i.e. transaction of the Company of material nature, with promoters or the management, their subsidiaries or relatives etc. that may have potential conflict with the interests of Company at large.
- > Reviewing with the management, external and internal auditors, the adequacy of internal control systems.
- Peviewing the adequacy of internal audit function, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.
- Discussion with internal auditors any significant findings and follow up there on.
- Reviewing the findings if any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- Discussion with external auditors before the audit commences, nature and scope of audit as well as have post-audit discussion to ascertain any area of concern.
- Review in the Company's financial and risk management policies.
- > To look into the reasons for substantial defaults in the payment to the depositors, debentures, shareholders (in case of nonpayment of declared dividend) and creditors.
- It shall have discussions with the auditors periodically about internal control systems, the scope of audit including the observations of the auditors and review the quarterly, half-yearly and annual financial statements before submissions to the Board.
- It shall ensure compliance of internal control systems.

Audit Committee met four times on 30/05/2017, 14/08/2017, 13/11/2017 and 13/02/2018.

All the Meetings were also attended by the Auditors of the Company.

NOMINATION AND REMUNERATION COMMITTEE:

Composition and terms of reference:

In Compliance of section 178 of Companies Act, 2013 the Nomination and Remuneration Committee is constituted of Four (4) Directors, and an Independent Director acts as the Chairman of the Committee. The Committee's terms of reference includes, inter-alia, reviewing and recommending to the Board – the salary, commission, other benefits, service agreements and employment conditions of the Whole-time and the Managing Director and to approve the selection, appointment and remuneration of relatives of Directors for holding an office of profit pursuant to Section 188 of the Companies Act, 2013.

Date(s) on which the meeting(s) were held

During the financial year ended 31st March 2018, four (4) Committee Meetings were held on 30/05/2017, 14/08/2017, 13/11/2017 and 13/02/2018.

Details of remuneration paid to the Directors of the Company are as follows:

Managing Director:

The present remuneration of the Managing Director includes a salary of ₹ 200000/- per month and other perquisites, as approved by the Remuneration committee and shareholders at the AGM held on 30th September, 2015. For the financial year 2017-18, the remuneration payable to MR. JAGDISH AGRAWAL is reviewed by the Remuneration Committee.

Non-Executive Directors:

The Non-Executive Directors on the Board of your company are very senior and experienced professionals, and play a crucial role in defining the overall growth strategy of the company. They also play a pivotal role in safeguarding the interests of the investors at large by playing an appropriate control role. Their active involvement in the company's business processes and their independent views ensure a very high level of governance in the company.

The Non-Executive directors are providing honorary services and have not been paid any salary, sitting fees, performance based incentives or any stock options during the financial year 2017-18.

Relatives of the Directors

The Chief Financial Officer of the Company, MR. SUMIT J. AGRAWAL, is related to the Managing Director, MR. JAGDISH AGRAWAL and another promoter director, MRS. ABHA AGRAWAL. As such, his appointment and remuneration is approved by the Remuneration Committee and the shareholders. The present remuneration of the CFO is ₹ 175,000/- per month, including salary and other perquisites, as approved by the Remuneration Committee. For the financial year 2017-18, the remuneration payable to MR. SUMIT AGRAWAL is reviewed by the Remuneration Committee.

STAKEHOLDER RELATIONSHIP COMMITTEE:

Composition and terms of reference:

As per sub-section (5) section 178 of Companies Act, 2013 the Share transfers committee has been merged in to STAKEHOLDER RELATIONSHIP COMMITTEE.

The Board of Directors of the Company has constituted the Stakeholder Relationship Committee which is chaired by Non Executive Director to specifically look into the redressal of shareholders queries and complaints.

The terms of reference of the Committee include, inter-alia, the following:

- 1. To specifically look into queries and complaints received from the shareholders of the Company,
- 2. To oversee the performance of the Registrar and Transfer Agent of the Company, and
- 3. To recommend measures for overall improvement in the quality of services to the investors.
- 4. To effect transfer of shares;
- 5. To effect transmission or deletion of shares;
- 6. To issue duplicate share certificates, issue of certificate on receipt of requests for rematerialisation, consolidatin or split of share certificates:
- 7. To approve the register of members as on the record date(s) and/ or book closure dates for receiving dividends and other corporate benefits:

INVESTOR COMPLAINTS	
1 Pending at the beginning of the year	NIL
2 Received during the year	NIL
3 Disposed of during the year	NIL
4 Remaining unresolved at the end of the year	NIL

Date(s) on which the meeting(s) were held

During the financial year 2017-18, the Committee met four times on 30/05/2017, 14/08/2017, 13/11/2017 and 13/02/2018. There were no pending complaints at the end of the financial year 2017-18.

III. General Body Meetings:

The venue and the time of the last three Annual General Meetings of the Company are as follows:

Year	Location	Meeting Date	Time	No. of Special Resolution set Out at the AGM
2016-2017	Survey No.179/1,	30/09/17		0
2015-2016	Village : Vasna-Iyava	30/09/16	3.00 p.m.	0
2014-2015	Ta. Sanand,	30/09/15	1	1

All special resolutions set out in the notices for the Annual General Meetings were passed by the shareholders at the respective meetings with requisite majority.

IV. Disclosures:

a) Disclosures on materially significant related party transactions:

Your Company has not entered into any transaction of a material nature except transactions with related parties which are furnished under Notes to the Financial Statements as stipulated under Indian Accounting Standard 24 (Ind AS-24), with the Promoters, Directors or the Management, their subsidiaries or relatives etc. All transactions were carried out on an arms-length basis and were not prejudicial to the interest of the Company.

b) Disclosures on non-compliances by the Company:

Your Company has complied with all the requirements of the Stock Exchange(s) and the Securities Exchange Board of India on

matters related to Capital Markets or any other matter, as may be applicable from time to time. There were no penalties imposed or strictures passed against the Company by the statutory authorities in this regard.

c) Disclosure of Accounting Treatment:

Your Company follows Accounting Standards prescribed by the Companies Accounting Standard Rules, 2006 and relevant provisions of the Companies Act, 2013. In preparation of financial statements, the Company has not adopted a treatment different from that prescribed in the Accounting Standards.

d) Details of compliance with mandatory and non-mandatory requirements of Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations 2015 of the Listing Agreement:

As already mentioned in the Director's Report, the provisions of the Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations, 2015, do not apply to the Company. However, the company has voluntarily chosen to adopt and follow certain provisions of the Regulation 27 and suitable applicable provisions of SEBI (LODR) Regulations 2015.

The company complies with all the mandatory requirements of the SEBI (LODR) Regulations 2015 with regard to corporate governance.

e) Vigil mechanism

The company has established vigil mechanism for directors, employees and other stakeholders to report concerns about unethical behaviour, actual or suspected fraud or violation of the company's code of conduct or the ethical policy.

The company has provided opportunities to encourage employees to become whistle blowers. It has also ensured a mechanism within the same framework to protect them from any kind of harm. It is hereby affirmed that no personnel has been denies access to the audit committee.

1. AGM for the F.Y 2017-18	29/09/2018 at 3.00 p.m at Survey No.179/1, Village: Vasna-Iyava, Ta. Sanand, Dist. A-bad					
2. Date of Book closure		9/2018 (both days inclusive)	·			
3. Listing on Stock Exchanges		524400) & ASE (Scrip Co				
4. Share Registrar			ndustrial Estate, Saki Vihar R	oad, Sakinaka,		
	Mumbai – 400072,	Maharashtra.				
5. Share Transfer System	The shares of the o	company are compulsorily tr	aded in dematerialized form.	Shares received in physical		
	form are transferre	d within a period of 30 days	from the date of lodgement s	ubject to documents being valid		
	and complete in all	respects				
6. De-materlisation of Shares	As on 31/03/18, ap	prox. 80% shares of the cor	npany were held in de-materi	alized form		
7.Market Data : High, Low	Month	High	Low	Volume (Nos)		
during each month in last	Apr-17	22.40	17.85	40381		
financial year	May-17	23.90	19.50	32903		
	Jun-17	21.95	18.60	9819		
	Jul-17	21.85	14.90	33295		
	Aug-17	20.95	18.05	7304		
	Sep-17	22.60	17.15	13012		
	Oct-17	25.00	18.60	35903		
	Nov-17	24.90	18.90	58436		
	Dec-17	25.10	20.40	17221		
	Jan-18	27.00	20.65	52095		
	Feb-18	22.85	18.80	21491		
	Mar-18	22.75	19.15	3783		

GREEN INITIATIVE IN CORPORATE GOVERNANCE:

Pursuant to Circular No. 17/2011 dated 21st April, 2011 and Circular No. 18/2011 dated 29th April, 2011, Ministry of Corporate Affairs (MCA) has launched "Green Initiative in Corporate Governance" whereby the companies are allowed to send notices, documents and other communication to the shareholders in electronic mode. In view of the above circulars issued by MCA, your Company proposes to send documents like the Notice convening the general meetings, Financial statements, Directors' Report, Auditors' Report, etc to the email address provided by you to your Depository Participant (DP). Your Company encourages its shareholders to support the "Green Initiative" by registering their email addresses with their respective depositories/ Company's Registrar and Transfer Agent and intimate changes in the email address from time to time.

MANAGEMENT DISCUSSION & ANALYSIS REPORT

GENERAL INFORMATION ABOUT THE COMPANY

The company is engaged in the business of manufacturing of various APIs (Active Pharma Ingredients) and drug intermediates. It has built up a reputation as a manufacturer of "high quality" products and is known for its ethical dealings in business. The company supplies its products to leading pharmaceutical companies of India. The products are also being exported to various countries across the world.

NATURE OF THE INDUSTRY

The Indian API industry has been facing a challenging business environment for last few years. With opening up of the Indian markets and signing of the WTO arrangement, the imported APIs and Intermediates became available at a very competitive price. This impacted the indigenous API and Intermediates manufacturers, who could not compete with the imported pricing. The Indian API industry has also been affected by stringent pollution control norms. Presently, almost 60-70% of total APIs consumed in India are imported. Over a period of time, the manufacturing capabilities & capacities for APIs in India has gone down. However, the present Govt. has recognized this fact and has affirmed its commitment to encourage domestic API industry by introducing special measures for its development.

OPPORTUNITY AND THREAT:

The biggest threat for the API industry is from imports. Other threats include requirement of resources for continuous up gradation of the facility as per the cGMP standards. This is especially more important for small scale industries like your Company.

However, with the Govt. focusing on the API industry, it is likely to come out with some measures to encourage the domestic API industry. Your company, with it's built up reserves and debt free status, is in a good position to take advantage of any such measures declared by the Govt.

FUTURE OUTLOOK:

The management's opinion on the future outlook for the Company is given under the Directors' Report forming part of the Annual Report of the company.

INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

The Company has adequate and effective internal controls to provide reasonable assurance on achievement of its operational, compliance and reporting objectives.

The Company has deployed controls through its policies and procedures. It helps the Management to accomplish its objectives by bringing a systematic and disciplined approach to improve the effectiveness of risk management towards good corporate governance. The Directors handle most of the day to day functions. The Directors are regularly looking after all the key areas of the operations.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

The management's view on the business operations and financial performance of the company, including export performance and earnings, is given under the Directors' Report forming part of the Annual Report of the company.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

The Company's operations are managed by technically and educationally qualified staff at all levels, who in turn are guided and supervised by the Directors of the Company. During the year under review, the company has increased the number of employees to better look after the various operations and to prepare for a better growth in the future.

CAUTIONARY STATEMENT:

Statement in the Management Discussion and Analysis, describing the Company's objective, projections and estimates are forward looking statements and progressive within the meaning of applicable security Laws and Regulations. Actual results may vary from those expressed or implied, depending upon economic conditions, Government Policies and other incidental factors.

DECLARATION OF COMPLIANCE WITH THE CODE OF CONDUCT

I hereby confirm that the company has obtained from all the members of the Board and employees at senior management level, affirmation that they have complied with the code of conduct for Board of Directors and senior management level employees.

For and on behalf of the Board

Sd/-

Place: Ahmedabad Jagdish Agrawal Dated: 29th May, 2018 Managing Director

CERTIFICATE PURSUANT TO REGULATION 17(8) OF THE LISTING REGULATIONS

Mr. Jagdish Agrawal, Managing Director and Mr. Sumit Agrawal, CFO of the company shall certify that, to the best of their knowledge and belief:

- (a) They have reviewed the balance sheet and profit and loss account and all its schedules and notes on accounts, as well as the cash flow statements and the Directors' Report:
- (b) These statements do not contain any materially untrue statement or omit any material fact nor do they contain statements that might be misleading;
- (c) These statements together present a true and fair view of the company, and are in compliance with the existing accounting standards and / or applicable laws / regulations;
- (d) They are responsible for establishing and maintaining internal controls and have evaluated the effectiveness of internal control systems of the company; and they have also disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, and what they have done or propose to do to rectify these:
- (e) They have also disclosed to the auditors as well as the Audit Committee, instances of significant fraud, if any, that involves management or employees having a significant role in the company's internal control systems; and
- (f) They have indicated to the auditors, the Audit Committee and in the notes on accounts, whether or not there were significant changes in internal control and / or of accounting policies during the year.

For and on behalf of the Board

Sd/-

Sd/-

Place: Ahmedabad Dated: 29th May, 2018 Jagdish Agrawal Managing Director Sumit Agrawal CFO

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ISHITA DRUGS AND INDUSTRIES LTD.

Report on the Financial Statements

We have audited the accompanying financial statements of ISHITA DRUGS AND INDUSTRIES LTD. ("The Company"), which comprise the Balance Sheet as at 31/03/2018, the Statement of Profit and Loss, the cash flow statement for the year ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to

the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31/03/2018, and its Profit and it's cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order,2016("the Order") issued by the Central Government of India in terms of sub section (11) of section 143 of the Companies Act, 2013. We give in the "Annexure A" statements on the matters specified in paragraphs 3 and 4 of the order, to the extent applicable.

As required by Section 143 (3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and the cash flow statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31/03/2018 taken on record by the Board of Directors, none of the directors is disqualified as 31/03/2018 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2016, in our opinion and to the best of our information and according to the explanations given to us:
- The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
- The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
- There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For Pratik Kaushikkumar Kikani Chartered Accountants M. No.180309

22

Date: 29th May, 2018

Place: Ahmedabad

25th ANNUAL REPORT 2017-18

ANNEXURE - A

Reports under The Companies (Auditor's Report) Order, 2016 (CARO 2016) for the year ended on 31st March 2018

To,

The Members of ISHITA DRUGS AND INDUSTRIES LTD.

(1) In Respect of Fixed Assets

- (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
- (b) Fixed assets have been physically verified by the management at reasonable intervals; No material discrepancies were noticed on such verification.
- (c) Yes, in the name of the company.

(2) In Respect of Inventories

Physical verification of inventory has been conducted at reasonable intervals by the management and no major discrepancies have been noticed.

(3) Compliance under section 189 of The Companies Act, 2013

The company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.

- (a) This clause is not applicable to the Company as there was no loans, secured or unsecured to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.
- (b) This clause is not applicable to the Company as there was no loans, secured or unsecured to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.
- (c) This clause is not applicable to the Company as there was no loans, secured or unsecured to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.

(4) Compliance under section 185 and 186 of The Companies Act, 2013

This clause is not applicable to the Company as there were no loans, investments, guarantees and security provided to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.

(5) Compliance under section 73 to 76 of The Companies Act, 2013 and Rules framed there under while accepting Deposits

During the year no deposit has been accepted by the company and accordingly this clause is not applicable.

(6) Maintenance of cost records

The Company is not required to maintain cost records pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013.

(7) Deposit of Statutory Dues

- (a) N.A.
- (b) There is no dispute with the revenue authorities regarding any duty or tax payable.

(8) Repayment of Loans and Borrowings

Based on our audit procedures and as per the information

and explanations given by the management, we are of the opinion that the company has not defaulted in repayment of dues to a financial institution, bank of debenture holders.

(9) Utilization of Money Raised by Public Offers and Term Loan For which they Raised

The company has not raised any money by way of initial public offer or further public offer (including debt instruments) and term loans. Hence this clause is not applicable.

(10) Reporting of Fraud During the Year

Based on our audit procedures and the information and explanation made available to us no such fraud noticed or reported during the year.

(11) Managerial Remuneration

Managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.

(12) Compliance by Nidhi Company Regarding Net Owned Fund to Deposits Ratio

As per information and records available with us The company is not Nidhi Company.

(13) Related party compliance with Section 177 and 188 of companies Act - 2013

Yes, All transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the applicable accounting standards.

(14) Compliance under section 42 of Companies Act - 2013 regarding Private placement of Shares or Debentures

Not applicable as no preferential allotment made during the year.

(15) Compliance under section 192 of Companies Act – 2013

The company has not entered into any non-cash transactions with directors or persons connected with him.

(16) Requirement of Registration under 45-IA of Reserve Bank of India Act, 1934

The company is not required to be registered under section 45-IA of the Reserve Bank of India Act.

For Pratik Kaushikkumar Kikani

Chartered Accountants
M. No. 180309

Date: 29th May, 2018 Place: Ahmedabad

"Annexure B"

To the Independent Auditor's Report of even date on the Standalone Financial Statements of ISHITA DRUGS AND INDUSTRIES LTD.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of ISHITA DRUGS AND INDUSTRIES LTD. Company Limited ("The Company") as of March 31, 2018 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence amount the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and operating effectiveness of internal control based on the assessed risk. The procedures selected depend upon on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issues by the Institute of Chartered Accountants of India.

For Pratik Kaushikkumar Kikani Date: 29th May, 2018 **Chartered Accountants** Place: Ahmedabad

M. No.180309

BALANCE SHEET AS AT 31ST MARCH, 2018

(Amount in ₹)

S.N	PARTICULARS	Note No		As at 31/03/2018	As at 31/03/2017
I	ASSETS				
1	NON-CURRENT ASSETS				
	(a) PROPERTY, PLANT AND EQUIPMENT	l A	11879886		10171144
	(b) FINANCIAL ASSETS				
	(i) INVESTMENTS	В	1592254		1592254
	(ii) LOANS	l c	498200		498200
	TOTAL(1)			13970340	12261598
2	CURRENT ASSETS				
2		D	7200006		E616204
	(a) INVENTORIES		7200886		5616304
	(b) FINANCIAL ASSESTS (i) INVESTMENTS	E	20026505		05061000
	**	-	29936585		25361292
	(ii) TRADE RECEIVABLES	_	8215528		17040975
	(iii) CASH AND CASH EQUIVALENTS	F	6752062		4225186
	(iv) OTHER BALANCES WITH BANK	G	5209138		6899063
	(v) LOANS	H	92682		314590
	(c) OTHER CURRENT ASSETS	'	168440	F7F7F004	151176
	TOTAL(2)			57575321	59608586
	TOTAL ASSETS(1+2)			71545661	71870184
I	EQUITY AND LIABILITIES				
1	<u>EQUITY</u>				
	(a) EQUITY SHARE CAPITAL	J	29903000		29903000
	(b) OTHER EQUITY	K	30720893		28242900
	TOTAL (1)		Γ	60623893	58145900
2	NON-CURRENT LIABILITIES				
_	(a) FINANCIAL LIABILITIES				
	(i) BORROWINGS	l L	849414		0
	(b) DEFERRED TAX LIABILITIES (NET)	-	593317		639429
	TOTAL(2)			1442731	639429
3	CURRENT LIABILITIES				
3	(a) FINANCIAL LIABILITIES				
	(i)BORROWINGS	M	25262		72229
	(ii)TRADE PAYABLES	I	5616188		11816720
	(ii) I RADE PAYABLES (b) OTHER CURRENT LIABILITIES	NI NI	418325		61652
	(c) PROVISIONS	N O	1156530		908840
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		1		
	(d) CURRENT TAX LIABILITES (NET)		2262732	9479037	225415 13084856
	TOTAL(3) TOTAL LIABILITIES(1+2+3)		+		71870184
lata	Accounts & Significant Accounting Policies	<u> I</u> Р		71545661	/10/0184

As per our attached report of even date.

Sd/-Sd/-Sd/-Jagdish Agrawal **Govind Gupta** For Pratik Kaushikkumar Kikani

Managing Director Director **Chartered Accountants**

Sd/-Sd/-**Sumit Agrawal** Mrs.Abha Agrawal

Director CFO Ahmedabad

Dated: 29th May, 2018

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED ON 31ST MARCH, 2018

(Amount in ₹)

					(Alliount iii \)
S.N	PARTICULARS	Note No		Year 2017-18	Year 2016-17
	INCOME				
1	REVENUE FROM OPERATIONS		68428938		64395850
II	OTHER INCOME	PL-1	1762122		809979
III	TOTAL INCOME (I+II)			70191060	65205829
IV	EXPENSES:				
	(a) COST OF MATERIAL CONSUMED	PL-2	47674163		36901501
	(b) PURCHASE OF STOCK IN TRADE	PL-3	922500		1546897
	(c) CHANGES IN INVENTORIES OF FINISHED GOODS,	PL-4	(1270590)		1273850
	WORK-IN-PROGRESS AND STOCK-IN-TRADE				
	(d) EMPLOYEE BENEFIT EXPENSES	PL-5	7999615		6916963
	(e) FINANCIAL CHARGES	PL-6	1126025		445632
	(f) DEPRECIATION		1360905		1399814
	(g) MANUFACTURING AND OTHER EXP.	PL-7	9146559		14151054
	TOTAL EXPENSES			66959177	62635711
٧	PROFIT FOR BEFORE TAX (III-IV)			3231883	2570118
VI	TAX EXPENSE				
	(a) CURRENT TAX			800000	850000
	(b) DEFERRED TAX			(46111)	(104487)
VII	PROFIT(LOSS) FOR THE YEAR			2477994	1824605
VIII	OTHER COMPREHENSIVE INCOME			0	0
IX	TOTAL COMPREHENSIVE INCOME FOR THE YEAR			2477994	1824605
X	EARNING PER EQUITY SHARE (FACE VALUE ₹ 10				
	EACH)				
	(a) BASIC			0.83	0.61
	(b) DILUTED			0.83	0.61
Notes o	n Accounts & Significant Accounting Policies	P			

As per our attached report of even date.

Sd/-For Pratik Kaushikkumar Kikani

Chartered Accountants

Sd/-Jagdish Agrawal Managing Director

Sd/-**Govind Gupta** Director

Sd/-Mrs.Abha Agrawal

Director Ahmedabad

Dated: 29th May, 2018

Sd/-**Sumit Agrawal**

CFO

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2018

(Amount in ₹)

			(Amount m v)
		For the Year 2017-18	For the Year 2016-17
A Cash flo	ow from operating activities :		
Profit bef	fore tax	3231883	2570118
Add :	Depreciation	1360905	1399814
	Interest & Other financial charges	1126025	445632
Less:	Interest received	426043	1199414
	Dividend received	897	5192
	Income from Investments	765826	339844
Operating pr	ofit before change in working capital	4526046	2871113
Add :	Trade Debtors	8825447	1767101
	Decrease / (Increase) in Inventory	(1584582)	2038255
	Decrease /(Increase) in Loans and advances	132097	83848
Less:	Provision for Taxation	800000	850000
	Trade creditors, Current liabilities & Provisions	3878580	737487
Net cash ger	nerated from operating activities (A)	7220428	5172830
B Cash infle	ow from investing activities :		
Add :	Investment sold / (purchased)	(4575293)	(5415005)
	Dividend received	897	5192
	Income from Investments	765826	339844
Less:	Investment in fixed assets	3069647	438103
Net cash ger	nerated from investing activities (B)	(6878217)	(5508072)
C Cash flow	v from financial activities :		
Add :	Interest received	426043	1199414
Add :	Borrowing	1194722	(11239789)
Less:	Interest & Other financial charges	1126025	445632
Net cash ger	nerated from financial activities (C)	494740	(10486007)
Net Increase	/(decrease) in Cash & Cash Equivalents (A+B+C)	836952	(10821248)
Opening bala	ance of Cash and cash equivalents & Other Bank Balances	11124250	21945498
Closing balar	nce of Cash and cash equivalents & Other Bank Balances	11961202	11124250
Net Increase	/(decrease) in Cash & Cash Equivalents & Other Bank Balances	836952	(10821248)
Note : Figure	es in bracket indicate negative value		

Correctly extracted from Audited accounts of the Company

olymia Agrawai Sumit Guyta Sumit

Director Director CFO

Ahmedabad

Dated: 29th May, 2018

Auditors' Certificate

We have verified the above cash flow statements of Ishita Drugs And Industries Limited has been compiled from and is based on the balance sheet as at 31st March 2018 and the related statement of profit and loss for the year ended on that date. 2. The above cash flow statement has been prepared under the indirect method as set out in the Accounting Standard (IndAS -7)- Statement of Cash Flow.

For Pratik Kaushikkumar Kikani

Place : Ahmedabad Dated : 29th May, 2018 Chartered Accountants

25th ANNUAL REPORT 2017-18

ISHITA DRUGS AND INDUSTRIES LTD.

NOTES:

A PROPERTY, PLANT & EQUIPMENT

	Gross BI	lock		Depreciation			Net Block			
Particulars	As at 01/04/17 ₹	Addition ₹	Deduction ₹	As at 31/03/18 ₹	As at 01/04/17 ₹	Addition ₹	Deduction ₹	As at 31/03/18 ₹	As at 31/03/18 ₹	As at 31/03/17 ₹
Factory Land	904811			904811					904811	904811
Plant and Machinery	21910443	1498000	-	23408443	19090628	391676		19482304	3926139	2819815
Laboratory Equipment	1938298	45714		1984012	1364868	69015		1433884	550128	573429
Cylinders	14441			14441	14441			14441		
Effluent Treatment Plan	1608641			1608641	1528209			1528209	80432	80432
Factory Building	5905137			5905137	3907263	169542		4076805	1828332	1997875
Office Building	1264568			1264568	468180	20947		489127	775441	796388
Furniture and Fixtures	2125295			2125295	1269051	128139		1397190	728105	856244
Office Equipment	910069	99257		1009327	501457	74175		575631	433695	408613
Computers	716831	66676		783507	687918	38621		726539	56968	28913
Vehicles	4281051	1360000		5641051	2576427	468789		3045216	2595835	1704624
Total	41579585	3069647		44649232	31408441	1360905		32769346	11879886	10171144
Previous Year	41141482	438103		41579585	30008628	1399814		31408441	10171144	11132854

(Amount in ₹)

Notes			As at 31-Mar-18	As at 31-Mar-17
В	NON CURRENT INVESTMENT :			
	(a) Unquoted			
	500 Equity Shares of Textile Traders Co-operative		12500	12500
	Bank Ltd.each of ₹. 25 fully paid up			
	70000 Shares of Umang Financial Services Ltd. each		700000	700000
	of ₹ 10/- fully paid up			
	3000 Shares of Anvi Lifesciences Pvt Ltd. each		600000	600000
	of ₹100/- fully paid up			
	Aggregate value of Unquoted Investment- At cost			
	₹1312500 (PY ₹.1312500)			
	(b) Quoted			
	204 Shares of Jet Airways (India) Ltd. each		224400	224400
	of ₹ 10/- fully paid up			
	[Market value ₹ 124338 (PY ₹ 107294)]			
	39 Shares of BSE Ltd. each		31434	31434
	of ₹ 2/- fully paid up			
	[Market value ₹ 29492 (PY ₹ 38128)]			
	80 Shares of Avenue Supermart Ltd. each		23920	23920
	of ₹ 10/- fully paid up			
	[Market value ₹ 106160 (PY ₹ 51036)]	-	4=000=4	4500054
_	NON CURRENT LOANS	Total	1592254	1592254
С	NON CURRENT LOANS		40000	40000
	Security Deposits		498200	498200
	(Unsecured Considered Good Unless Otherwise stated)	-	40000	40000
	INVENTORIES	Total	498200	498200
D	INVENTORIES:			
	As taken, valued and certified by the M.D.		0004444	000500
	Raw material (at cost)		3231144	889536
	Raw Material in transit (at cost)		0	2079000
	Work in Process (at cost)		3822220	2551630
	Packing, Fuel Etc. (at cost)	T.1.1	147522	96137
-	OUDDENT INVESTMENTS	Total	7200886	5616304
E	CURRENT INVESTMENTS			05004063
	Investments in units of Mutual Fund	T ()	29936585	25361292
		Total	29936585	25361292

ISHIT	TA DRUGS AND INDUSTRIES LTD.		25 th ANNUAL RE	PORT 2017-18
				(Amount in ₹)
Notes			As at 31-Mar-18	As at 31-Mar-17
F	CASH & CASH EQUIVALENTS :			
	Cash on hand Banks Balance		251974	1174114
	In Current Accounts		3390628	103078
	In EEFC Account	Total	3109461 6752062	2947994
G	OTHER BALANCES WITH BANK	Total	6/52002	4225186
	In Fixed Deposit Accounts		5209138	6899063
н	CURRENT LOANS:	Total	5209138	6899063
	(Unsecured - Considered good)			
	Advances recoverable in cash or kind or for value to be received		92682	314590
ı	OTHER CURRENT ASSETS:	Total	92682	314590
•	Prepaid Expenses		168440	151176
		Total	168440	151176
J	EQUITY SHARE CAPITAL (1) Authorised:			
	(1) Authorised : 35,00,000 Equity Shares of ₹ 10/- each		35000000	35000000
	(2) Issued, Subscribed and paid up:			
	29,90,300 Equity Shares of ₹ 10/- each fully paid up	T. 1. 1	29903000	29903000
K	OTHER EQUITY	Total	29903000	29903000
	(1) Capital Reserve			
	State cash Subsidy		1500000	1500000
	(2) General Reserve As per Last Balance sheet		26578400	24753795
	Add: Transfer surplus in statement of Profit & Loss A/c		2477994	1824605
			29056393	26578400
	(3) Shares Forfeited		164500 30720893	164500 28242900
L	NON CURRENT BORROWINGS		30720093	20242900
	ICICI Bank Ltd- Vehicle Loan		849414	0
М	CURRENT BORROWINGS:	Total	849414	0
IVI	Working Capital Facility from Bank (Secured by first charge on stocks and	fixed		
	assets of the Company)		0	72229
	Loans repayable on demand from Bank (Unsecured)		25262 25262	0 72229
N	OTHER CURRENT LIABILITIES		23202	12229
	(1) Current Maturities of Long Term Debts (Vehicle Loan)		392275	0
	(2) TDS Payable	Total	26050 418325	61652 61652
0	PROVISIONS	Total	410325	01002
	(1) Provisions For Employee Benefits		241093	110515
	(2) Others	Total	915437 1156530	798325 908840
		Total	1150550	900040
PL-1	OTHER INCOME:			
	Discount & Kasar		94738	(391567)
	Dividend Income		897	5192
	Interest Income		426043	1199414
	Income from Investments		765828	339844
	Foreign Exchange Gain/(Loss)	Total	474618 1762122	(342904)
PL-2	COST OF MATERIALS CONSUMED:	ividi	1702122	003373
- 	Consumption of Raw Material		47454695	36664260
	Consumption of Packing Mateial		219468	237241
		Total	47674163	36901501
PL-3	PURCHASES OF TRADED GOODS			
	Consumption of Goods Traded		922500	1546897
		Total	922500	1546897

ISHIT	A DRUGS AND INDUSTRIES LTD.		25 th ANNUAL RE	PORT 2017-18
				(Amount in ₹)
Notes			As at 31-Mar-18	As at 31-Mar-17
PL-4	Changes in inventories of finished goods,			
	work-in-progress and Stock-in-Trade			
	Inventory Adjustments			
	(a) Opening Stock Manufacturing Goods			
	Work in process		2551630	3825480
	Work in process		2551630	3825480
	(b) Closing Stock			
	Manufacturing Goods			
	Work in process		3822220	2551630
			3822220	2551630
	Net Inventory Adjustments (a-b)	Total	(1270590)	1273850
PL-5	EMPLOYEE BENEFITS EXPENSE			
	Salary & wages & Bonus		5397005	4386280
	Gratuity		43844	8943
	Staff Welfare Exp.		62975	76181
	Director's Remuneration Contribution for Provident Fund		2400000 48424	2400000 24945
	Contribution for FIGURE Fund Contribution for ESIC		48424 47367	24945
	Contribution for ESIC	Total	7999615	6916963
PL-6	FINANCIAL CHARGES:	rotar	7555010	0010000
	Interest		937972	162268
	Other financial charges		188052	283364
	•	Total	1126025	445632
PL-7	OTHER EXPENSES:			
Α	MANUFACTURING EXPENSE :			
	Stores & Spare		326837	414101
	Power & Fuel		1986004	2036943
	Repairs to Plant & machinery		225713	117170
	Conversion charges Laboratory Exp.		89860 68129	54130 68202
	Research & Development Expenses		146792	189407
	Excise duty on sales		1259104	6006827
	ETP Maintenance exp.		861326	342920
	·		4963765	9229700
В	ADMINISTRATIVE EXPENSE			
	Books & Periodicals		27013	29055
	Repairs To Building		63361	471073
	Repairs To Others		160180	266464
	Insurance Exp.		168130	185833
	Security Exp.		106752	64000 110446
	Printing & Stationery Exp. Postage & Telephones		167356	210761
	Office and General Exp.		456261	751467
	Motor Car Expenses		185254	211954
	Payment to Auditor		29000	29000
	Legal & Professional fees		300561	178037
	Listing, filling & license fees		300330	259289
	Share Transfer Exp.		42084	56614
	Rent, Rates & Taxes		1394423	928227
_	OF LUNG A DIOTRIPUTION TYPENOT		3400703	3752221
С	SELLING & DISTRIBUTION EXPENSE		407605	E71041
	Traveling & Conveyance Freight & Forwarding		407625 219315	571241 185453
	Sales Commission		145436	286099
	Advertisement		9715	126341
			782091	1169134
	GRAND TOTAL (A+B+C)		9146559	14151054

NOTE P: SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART OF BALANCE SHEET AND STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31.03.2018.

Significant Accounting Policies adopted by the Company in the preparation and presentation of the Accounts.

ACCOUNTING CONVENTION

The financial statements have been prepared in accordance with the Indian Accounting Standards (IndAS) notified under the Companies (Indian Accounting Standard) Rules, 2015, and stipulations as applicable under Section133 of the Companies Act, 2013, as amended from time to time, and other provisions of applicable laws.

These financial statements are prepared and presented under historical cost convention on accrual basis of accounting, except for certain assets and liabilities, which are to be measured at fair value, in accordance with IndAS.

FIXED ASSETS

Fixed assets are stated at historical cost less depreciation.

DEPRECIATION

Depreciation of Fixed Assets is calculated and provided as per Companies Act, 2013. The depreciation has been calculated considering the useful life of an asset as stipulated in Part C of Schedule II of Section 123 of the Companies Act 2013. However, in case of certain asset class, as detailed below, the useful life has been considered based on the present condition of the assets.:

- Computers & Data processing units: Against the stipulated useful life of 3 years, we have considered useful life of 5 years, as even 4 years old computers are presently in use.
- Office equipment: Against the stipulated useful life of 5 years, we have considered useful life of 10 years, based on the condition and our experience of the office equipment.

Apart from the above, for assets where the residual useful life is NIL as per the Part C, the carrying amount of the asset (after retaining the residual value) has been depreciated in the current year.

Depreciation on the additions is calculated pro rata from the date of additions. Depreciation is not provided on deletion of assets, as it has no effect on the results of the Company.

INVESTMENTS

Long term investments are stated at cost less provision for diminution, if any, in the value of such investments. Diminution in the value is provided for where the management is of the opinion that the diminution is of a permanent nature. Short term investments are valued at lower of cost or net realizable value.

INVENTORIES

- a) Packing & fuel are valued at cost on FIFO Basis.
- b) Raw materials are valued at cost on FIFO Basis.
- c) Finished goods are valued at cost or market value whichever is lower.
- d) Work in progress is valued at cost.

MODVAT

Cenvat benefit is accounted on accrual basis on purchases of raw materials and capital goods and on actual payment basis on input services. The Cenvat benefit is appropriated against payment of excise duty on clearance of excisable goods.

SALES

Sales are accounted exclusive of Goods and Services Tax (GST) post GST implementation and inclusive of Excise Duty.

FOREIGN CURRENCY TRANSACTIONS

Foreign Currency transactions are recorded at exchange rate prevailing on the date of transaction/ realization. Current Assets / Liabilities are taken at transaction value. Diminution in the value is provided for where the management is of the opinion that the diminution is of a permanent nature. The resultant difference, if any, on realization is recognized in the profit & loss account.

EXCISE DUTY

As per past practice, the Company is accounting for liability for excise duty on finished goods lying in factory premises as and when the same are cleared. Accordingly, estimated liability amounting to ₹NIL (P.Y. ₹ NIL) in respect of such goods as on 31.03.2018 has not been provided for in the accounts and hence not included in valuation of inventory. Non-provision of this liability will not affect profit for the year.

CUSTOM DUTY

Custom duty is charged in the year when it is paid.

PROVISION FOR RETIREMENT BENEFITS

Gratuity: The Company's obligations towards gratuity to employees has been provided for at actuals and other retirement benefits as per policy of the company have been provided for as per IndAS-19. The same have been charged in the profit and loss of the Company.

Provident Fund: The employer and employee make statutory contribution towards the Government's Provident Fund and the same is charged in the profit and loss of the Company.

EXPENSES

Material known liabilities are provided based on available information/estimates.

TIMING REVENUE RECOGNITION

In appropriate circumstances, revenue (income) is recognized when no significant uncertainty as to measurability or collectability exists.

TAXATION

Provision for taxation is made based on the current tax rates in force.

Deferred tax charge or credit (reflecting the tax effect of timing difference between accounting income and taxable income for the period) is determined in accordance with the IndAS-12. The deferred tax charged or credited and the corresponding deferred tax liabilities or assets are recognized using the tax rate that have been enacted or subsequently established by the Balance Sheet date. Deferred tax assets are recognized and carried forward to the extent that there is a reasonable

25th ANNUAL REPORT 2017-18

certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised.

CASH FLOW STATEMENT

Cash flows are reported using indirect method, whereby profit before tax is adjusted for the effects of transactions of a non cash nature and any deferrals or accruals of past and future cash receipts and payments. The cash flows from regular operating, investing and financing activities of the Company are segregated.

CONTINGENT LIABILITIES

All liabilities have been provided for in the accounts except liabilities of a contingent nature, which have been disclosed at their estimated value in the notes on accounts.

IMPAIRMENT OF ASSETS

Impairment loss, if any, is recognized in accordance with the accounting standard IndAS-36.

PRIOR PERIOD ITEMS

Material items of prior period non-recurring and extra ordinary items, if any, are disclosed separately.

NOTES:

- 1. Tax provision for income tax has been made as per the Income Tax Act, 1961.
- 2. Debit and credit balances in respect of debtors, loans and advances and creditors are subject to confirmation and reconciliation.
- 3. In accordance with the IndAS-21, net profit of ₹ 4.75 lacs (PY loss of ₹ 3.43 lacs) due to foreign exchange fluctuations arising on foreign currency transactions has been considered in the Profit and Loss Account.
- 4. In the year under review, the Company has provided the gratuity ₹ 43844 (P.Y. ₹ 8943) towards gratuity calculated up to the date of Balance Sheet date according to the Gratuity Act on incremental basis.
- The company has accounted for deferred tax assets of ₹46111 (P.Y. deferred tax assets of ₹104487) for the year under review as per IndAS-12 in the profit and loss account.
- Contingent liability to the extent not provided for ₹ NIL (P.Y ₹ NIL)
- 7. Previous year figures have been regrouped and reclassified wherever necessary to be in conformity with the current year figures.
- 8. Estimated amount of capital contracts remaining to be executed and not provided for net of advance paid ₹ NIL (PY ₹ NIL).

9. Managerial Remuneration paid:

 2017-18
 2016-17

 Mg. Dir.
 Mg. Dir.

 (a) Salary₹
 2400000
 2400000

 (b) Perks/ Reimbursement₹
 ---- ----

10. Payment to Auditors (₹)

<u>2017-18</u>	2016-17
15000	15000
ks 5000	5000
7000	7000
2000	2000
	15000 ks 5000 7000

- 11. The Company has not received any information from any of the suppliers of their status as Small Scale Industrial Unit. Hence, the amounts due to them outstanding as at 31st March 2018 is not ascertainable.
- 12. Related party disclosures as per the Accounting Standard AS-18 issued by the Institute of Chartered Accountants of India:
 - a. List of related parties
 - Subsidiaries: The Company does not have any subsidiary Company.
 - Key Management personnel
 Mr. Jagdish Agrawal
 Mr. Sumit Agrawal
 - ii. Relatives of Key Management Personnel Ishita Pharmaceuticals
 Anvi Lifesciences Pvt Ltd
 J & J Chemicals
 Umang Financial Services Ltd
- b. Transactions / balances outstanding with Related parties

Particulars	Key Management Personnel Amount in ₹	Relatives of Key Management Personnel Amount in ₹
Managerial Remuneration	4500000	
Sales of Goods / Services		16342391
Purchases of Goods /Services		17073432
Investment in equity shares/ Share Application Money		1300000
Loans/advance at year end		300000
Lease Rent		1236000

Note: Related parties are as identified by the Company and relied upon by the auditors.

13. Earning per Shares (EPS) as per Indian Accounting Standard AS-33

Particulars	2017-18	2016-17
T difficulties	Amount ₹	Amount ₹
Profit after Tax	2477994	1824605
Weighted Average no. of equity shares of ₹ 10 each		
Basic	2990300	2990300
Diluted	2990300	2990300
EPS (₹ .)		
Basic	0.83	0.61
Diluted	0.83	0.61

Additional information pursuant to the provisions of Companies Act, 2013.

14. Quantitative details and other information:

A Value of imports in rupees calculated on CIF basis in respect of;

^	value of imports in rupees calculated on on basis in respe	, , ,	Curr. Yr. ₹	Prev. Yr. ₹	
	Material		15686797	15588583	
В	Expenditure in foreign currency: Purchases of materials Miscellaneous Expenses Travelling and Conveyance Expenses and Other Expenses		2059553 39497 0	23353554 90741 70326	
С	Value of raw materials, stores and spares consumed :	₹	%	₹.	%
	(a) Value of raw material consumed :		76	<u> </u>	70
	Imported	16402486	34.56	16761647	45.72
	Indigenous	31052209	65.44	19902613	54.28
	·	47454695	100.00	36664260	100.00
	(b) Value of stores and spares consumed :				
	Indigenous	326837	100.00	414101	100.00
		326837	100.00	414101	100.00
D	Amount remitted in foreign currency on				
	account of dividend		NIL	NIL	
Е	Earnings in foreign exchange (₹)		6184057	3774691	

Signature to Notes A to P

Sd/- Sd/- Sd/- Sd/- Sd/- Sd/- For Pratik Kaushikkumar Kikani Chartered Accountants Jagdish Agrawal Managing Director Director

Sd/
Mrs.Abha Agrawal

Director

Ahmedabad

Dated: 29th May, 2018

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

Registration Details

Registration No. L24231GJ1992PLC017054 State Code 04

Balance Sheet Date 31-Mar-18

Capital raised during the year (Amount in thousands)

Public IssueNILRights IssueNILBonus IssueNILPrivate PlacementNIL

Position of Mobilisation and Deployment of Funds. (Amount in thousands)

Total Liabilities 71389 Total Assets 71389

Source of Funds

Paid up Capital29903Secured Loans849Reserves & Surplus30721Deferred Tax593

Current Liabilities 9323

Application of Funds

Net Fixed Assets 11880 Current Assets 57419

Investments 1592 Long term Loans & Advance 498

Performance of the Company (Amount in thousands)

Turnover 70191 Total expenditure 66959

Profit before tax 3232 Profit after tax 2478
Earning per Share Rs. 0.83 Dividend Rate (%) 0%

Generatic Names of Three Principal Products/services of Company.

(as per monetary terms)

Item Code No. (ITC Code)29419060Product DescriptionNORFLOXACINItem Code No. (ITC Code)29362920Product DescriptionNICOTINIC ACID

Item Code No. (ITC Code) 29359015

Product Description SULFONAMIDES

Note: Classification of products/services under ITC code being of a technical nature is not verified by the Auditors.

As per our attached report of even date.

Sd/- Sd/-

Mrs.Abha Agrawal
Director
Sumit Agrawal
CFO

Ahmedabad

Dated: 29th May, 2018


Registered Office : Survey No. 179/1 , Vasna Iyava, Sanand.

Form No. MGT-11
Proxy Form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Members			
Registered address :			
E-mail Id:			
Folio No. / Client Id:			
DP ID :			
I/We, being the holder(s) of hereby appoint	ofequity shares of ISHITA DRUGS AND INDUSTIRES	LIMITED,	
1. Name :	E-mail ld :		
Address:			
	Signature : E-mail Id :		
	Signature :		
as my/our proxy to attend of the Company, to be he	d and vote (on a poll) for me/us and on my/our behalf at the 25 th Annual Geleld on Saturday, 29 th September, 2018 and at any adjournment thereof.	neral Mee	eting
Sr. Particulars		For	Against
No.	IFOO		
ORDINARY BUSIN			
	d Profit & Loss Account for the year ended on 31st March, 2018, and the on that date, Directors' Report and the Auditors' Report thereon.		
2. Re-appointment of	Mrs. Abha Agrawal (DIN 01589479), as Director, who retires by rotation.		
Appointment of the remuneration	Auditors of the Company for the financial year 2018-19 and to fix their		
SPECIAL BUSINE	SS		
4. Special Resolution f	for Re-appointment of Mr. Jagdish Agrawal as Managing Director of the Company.		
Signed this	_ day of 2018		Affix 00 Paise Revenue
Signature of Share hold	er Signature of Proxy holder(s)	— L	Stamp
Note : This form duly con before the Meeting	npleted and signed must be deposited at the registered Office of the Company n	ot less tha	n 48 hours
			0.4
*			X
	ISHITA DRUGS AND INDUSTRIES LTD Registered Office: Survey No. 179/1, Vasna Iyava, Sanand.		
	Attendance Slip (To be handed over at the entrance of the meeting hall) 25 th Annual General Meeting - 29th September 2018		
DP ID :			
FOLIO No. :	No. of Shares held ——		
Survey no. 179/1, Vas Full name of Proxy (in BL	esence at the TWENTY FIFTH ANNUAL GENERAL MEETING of the C na Iyava, Sanand. Dist : Ahmedabad at 3.00 P.M. OCK LETTERS) ure		

Route Map of Venue of AGM



By Courier / Registered / Speed Post

Jo,

Direct Location Link: https://goo.gl/maps/hN3kt975EP82

If undelivered, please return to:

Ishita Drugs & Industries Limited
Regd. Office: Survey No. 179/1, Village: Vasna-Iyava,
Taluka: Sanand, District: Ahmedabad - 382 170.